| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL2RG; P64; CIDX; IMD4; SCIDX; IL-2RG; SCIDX1 |
| Entrez GeneID | 3561 |
| clone | 4A8F2 |
| WB Predicted band size | 42.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD132 (AA: extra 23-262) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD132(IL-2受体γ链)抗体的3篇模拟参考文献示例(仅供参考，非真实文献)：
---
1. **文献名称**：*Targeting CD132 in T-cell malignancies: A novel therapeutic approach*
**作者**：Smith A, et al.
**摘要**：研究CD132抗体通过阻断IL-2/IL-4/IL-7等细胞因子信号通路，抑制T细胞恶性肿瘤增殖，体外实验显示抗体可诱导肿瘤细胞凋亡并增强化疗敏感性。
2. **文献名称**：*Structural characterization of a neutralizing anti-CD132 monoclonal antibody*
**作者**：Li X, et al.
**摘要**：解析人源化CD132抗体的晶体结构，揭示其结合受体γ链的抗原表位，证实该抗体可抑制IL-15介导的NK细胞活化，为免疫调节治疗提供分子基础。
3. **文献名称**：*CD132 deficiency and antibody rescue in a murine model of X-linked SCID*
**作者**：Garcia-R, et al.
**摘要**：在CD132缺陷的X-SCID小鼠模型中，注射靶向CD132的激动型抗体部分恢复了T细胞发育，提示其在基因治疗中的潜在辅助作用。
---
**提示**：实际文献需通过PubMed、Google Scholar等平台搜索“CD132 antibody”“IL2RG antibody”等关键词获取。
CD132. also known as the common gamma chain (γc), is a critical subunit shared by multiple cytokine receptors, including those for IL-2. IL-4. IL-7. IL-9. IL-15. and IL-21. Encoded by the *IL2RG* gene, it plays a pivotal role in immune cell development, activation, and homeostasis by facilitating signal transduction through the JAK-STAT pathway. Defects in CD132 are linked to X-linked severe combined immunodeficiency (SCID-X1), a life-threatening condition characterized by absent T and NK cells and dysfunctional B cells.
CD132-specific antibodies are essential tools for studying γc-dependent cytokine signaling and immune dysregulation. In research, they enable receptor blocking, flow cytometric detection, and investigation of γc expression in immune subsets. Clinically, therapeutic antibodies targeting CD132 or its associated pathways are explored for modulating immune responses in autoimmune diseases, cancers, and SCID-X1 gene therapy. Some approaches aim to restore γc function or inhibit hyperactive signaling.
As a shared receptor subunit, CD132's broad immunological roles make it a focal point for both mechanistic studies and translational applications, bridging basic immunology with therapeutic innovation.
×
